Grifols in a massive sell-off - looking for opportunities
The chart is self-explanatory!
Price to earnings getting very low, company is solid and should see a bounce sooner or later at major support levels.
1.11 BMXN
123.58 BMXN
256.87 M
About GRIFOLS SA
Sector
CEO
Nacho Abia
Headquarters
Barcelona
Website
Employees (FY)
23.74 K
Founded
1940
ISIN
ES0171996095
FIGI
BBG0073Y4234
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.
Buy $GRFS - NRPicks 22 AprGrifols, S.A. is engaged in the acquisition, manufacture, preparation and sale of therapeutic products, mainly plasma derivatives. The company operates through the bioscientific, hospital, diagnostic, biosupplies and other divisions.
Buy $GRFS - NRPicks 11 MarGrifols, S.A. engages in the acquisition, manufacture, preparation and sale of therapeutic products, principally plasma derivatives. The company operates through the Bioscience, Hospital, Diagnostics, Bio Supplies and Others segments.
Revenue TTM 5.6B
Net Income TTM 208M
EBITDA TTM 894M
EBITDA mar
Predicción GRF 28-12-2021Predicción para GRF en Corto. Recomendada por nuestro algoritmo de IA. El horizonte temporal de la recomendación es 5 días.
Are we at the bottom yet?Grifols stock has been heavely punished during 2021.
First the pandemic difficulted the plasma collection. We must take into account the stimulus checks and the unemployment benefits from the US goverment wich might have disuaded people from going to the plasma collection centers to get some extra
GRF is set for actionA nice triangle at the end of a long way down. Even though we did not face the ultimate action, the chances are the stage is set for upside. The best case is to see the short-lived break down but the solo break up is valid as well.
GRIFOLS: Throw-back becoming a reality?After surpassing Fib 0.5, it looks like the stock is heading towards 0.382 level (21.81). Right now the company is immersed in a share repurchase program since 12/03/2021 and it has already acquired 19.23% of its €125 million valued shares objective. Maybe the company's financial advisers are playin
GRIFOLS: Results day coming on Feb 26. Then to the moon?68.2% of GRIFOLS revenues come from the US and Canada. Covid19 cases there seem to be decreasing. The company is delaying more and more its deadline of results for the phase III of the inmunoglobulina antiCovid-19, now until spring 2021.
If GRLS results are positive or better than expected (speciall
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of GRFP/N is 156.59 MXN — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange GRIFOLS SA stocks are traded under the ticker GRFP/N.
GRIFOLS SA is going to release the next earnings report on May 14, 2024. Keep track of upcoming events with our Earnings Calendar.
GRFP/N stock is 0% volatile and has beta coefficient of 1.30. Check out the list of the most volatile stocks — is GRIFOLS SA there?
One year price forecast for GRIFOLS SA has a max estimate of 351.38 MXN and a min estimate of 137.65 MXN.
GRFP/N earnings for the last quarter are 2.58 MXN whereas the estimation was 3.49 MXN which accounts for −26.11% surprise. Estimated earnings for the next quarter are 3.82 MXN. See more details about GRIFOLS SA earnings.
GRIFOLS SA revenue for the last quarter amounts to 27.42 B MXN despite the estimated figure of 29.32 B MXN. In the next quarter revenue is expected to reach 33.16 B MXN.
Yes, you can track GRIFOLS SA financials in yearly and quarterly reports right on TradingView.
GRFP/N stock hasn't changed in a week, the month change is a 0.47% rise, over the last year GRIFOLS SA has showed a 24.20% increase.
Like other stocks, GRFP/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GRIFOLS SA stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 23.74 K employees. See our rating of the largest employees — is GRIFOLS SA on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GRIFOLS SA technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GRIFOLS SA stock shows the sell signal. See more of GRIFOLS SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on GRIFOLS SA future price: according to them, GRFP/N price has a max estimate of 351.38 MXN and a min estimate of 137.65 MXN. Read a more detailed GRIFOLS SA forecast: see what analysts think of GRIFOLS SA and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GRIFOLS SA EBITDA is 24.36 B MXN, and current EBITDA margin is 17.90%. See more stats in GRIFOLS SA financial statements.